Avanir Pharmaceuticals (AVNR) Stock Falls Off After Yesterday's Gain

NEW YORK (TheStreet) -- Avanir Pharmaceuticals  (AVNR) spiked Wednesday afternoon after a court ruled in the company's favor in a patent litigation case, but the shares had fallen off considerably by the close of trading Thursday.

The stock dropped 6.63%, or 33 cents, to $4.65 at the closing bell. More than 11.2 million shares changed hands to easily surpass the average volume of 2,408,670. The stock had a range of $4.45 to $5.06 for the day and holds a 52-week range of $2.62 to $6.

On Wednesday, the U.S. District Court for the District of Delaware ruled in the company's favor in its patent infringement lawsuit against Par Pharmaceuticals and Impax Laboratories over NUEDEXTA.

Must Read: Warren Buffett's 10 Favorite Growth Stocks

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The latter two companies had Abbreviated New Drug Applications for generic versions of NUEDEXTA capsules for the treatment of pseudobulbar affect, a medical disorder characterized by sudden and uncontrollable episodes of crying or laughing. After a six-day bench trial, the court ruled in Avanir's favor.

"We are very pleased with the Court's decision, as it confirms our continued belief in the strength of the patents covering NUEDEXTA," said Avanir President and CEO Keith A. Katkin in a statement. "Our focus remains on making NUEDEXTA available to patients suffering from the debilitating condition of PBA. This decision provides twelve-plus years of market exclusivity for NUEDEXTA."  

NUEDEXTA is still the only FDA-approved item for pseudobulbar affect treatment, according to Avanir's statement.
AVNR Chart

AVNR data by YCharts

STOCKS TO BUY: TheStreet's Stocks Under $10 has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists